Easyfour-TT 0.5ml Vaccine

Easyfour-TT 0.5ml Vaccine that protects against four diseases namely tetanus, diphtheria, pertussis (whooping cough), and haemophilus influenzae type b. It contains the toxoid against these diease to trigger the immune response.

This vaccine is given routinely to infants in three doses at 6, 10, and 14 weeks of age. It is an adsorbed liquid formulation that is ready to use.

Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems. Also, let the medical healthcare team know if your child is allergic to any medicine.​

• Prevention of Tetanus
• Prevention of Pertussis
• Prevention of Diphtheria
• Prevention of Haemophilus influenzae Type b disease

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Easyfour-TT 0.5ml Vaccine  , but they disappear naturally within a few days as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team.

Some of the common side effects of the vaccine are:

• Irritability
• Vomiting
• Fever
• Diarrhea
• Local site pain
• Restlessness
• Drowsiness

• The Easyfour-TT 0.5ml Vaccine is given into the deltoid muscle of the upper arm. It is an intramuscular injection. Do not use the same injection or syringe for another vaccine, as there is a chance of interaction.
• This vaccine is given routinely to infants in three doses at 6, 10, and 14 weeks of age. It is an adsorbed liquid formulation that is ready to use. Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems.
• Also, let the medical healthcare team know if your child is allergic to any medicine.​
  

• Easyfour-TT 0.5ml is a vaccine that contains the toxoid of diphtheria, tetanus, pertussis, and Haemophilus Influenzae type b. When this vaccine is given to an individual then it stimulates the immune system to produce specific antibodies against the toxins, but doesn’t cause disease.
• These antibodies and memory cells formed after taking the injection identify and counteract the toxins and generate memory for it, and neutralize it with a stronger immune response upon subsequent exposure within a few hours. This provides immunity within 2 to 4 weeks and for many years.

• Gandhi, D. J., Dhaded, S. M., Ravi, M. D., Dubey, A. P., Kundu, R., Lalwani, S. K., ... & Dhingra, M. S. (2016). Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants. Human Vaccines & Immunotherapeutics, 12(4), 946-954. https://pubmed.ncbi.nlm.nih.gov/26580093/
• Dhingra, M. S., Rao, R., Bhat, S., Joshi, R., Kalra, V., Parikh, H. R., ... & Muzaffaruddin, M. (2010). Evaluation of the immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Shan 4) with EasyFourTM in Indian infants administered per EPI schedule: A phase III trial. Human vaccines, 6(7), 572-577. https://pmc.ncbi.nlm.nih.gov/articles/PMC3322520/
• Sharma, H. J., Patil, V. D., Lalwani, S. K., Manglani, M. V., Ravichandran, L., Kapre, S. V., ... & Shewale, S. D. (2012). Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process. Vaccine, 30(3), 510-516. https://pubmed.ncbi.nlm.nih.gov/22119927/
• Thang, H. V. (2015). Immunogenicity and safety of Quinvaxem®(diphtheria, tetanus, whole-cell pertussis, hepatitis B and haemophilus influenzae Type B vaccine) given to vietnamese infants at 2 to 4 months of age. The Southeast Asian journal of tropical medicine and public health. https://pubmed.ncbi.nlm.nih.gov/26867396/
• Li, Y., Li, R. C., Ye, Q., Li, C., Liu, Y. P., Ma, X., ... & Mesaros, N. (2017). Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Human vaccines & immunotherapeutics, 13(3), 588-598. https://pubmed.ncbi.nlm.nih.gov/27768515/